Field & Main Bank Sells 1,752 Shares of Danaher Corporation (NYSE:DHR)

Field & Main Bank trimmed its position in Danaher Corporation (NYSE:DHR - Free Report) by 65.7% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 915 shares of the conglomerate's stock after selling 1,752 shares during the period. Field & Main Bank's holdings in Danaher were worth $188,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. increased its position in shares of Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after acquiring an additional 99 shares during the last quarter. Heck Capital Advisors LLC bought a new position in Danaher in the 4th quarter valued at $27,000. Rialto Wealth Management LLC purchased a new stake in shares of Danaher during the 4th quarter valued at $34,000. Hurley Capital LLC bought a new stake in shares of Danaher during the 4th quarter worth $34,000. Finally, Dunhill Financial LLC boosted its holdings in shares of Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after buying an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president now directly owns 15,179 shares of the company's stock, valued at $3,005,442. This trade represents a 51.01% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.20% of the company's stock.

Danaher Stock Up 0.6%

Shares of NYSE DHR opened at $197.51 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The business has a 50-day moving average of $194.11 and a 200-day moving average of $209.06. The firm has a market capitalization of $141.35 billion, a price-to-earnings ratio of 38.35, a PEG ratio of 2.76 and a beta of 0.77. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher's payout ratio is currently 24.85%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on DHR shares. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. HSBC lowered their price target on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Argus reduced their price objective on Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. TD Cowen raised their target price on Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $248.61.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.